Herceptin News and Research

RSS

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

microRNAs (miRs) are small endogenous noncoding RNA molecules (20–23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome that act specifically as triggering molecules to control translational repression or mRNA degradation.

11 Mar 2016

New drug combination treatment makes breast cancer tumours disappear in just 11 days

Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their tumours shrink significantly or even disappear, according to results from a clinical trial.

11 Mar 2016

Understanding role of ethnicity, age in breast cancer prognosis

Although breast cancer is somewhat more aggressive in South Asian and Black women than in White women, this is largely due to age differences between ethnic groups in the UK, according to new research.

10 Mar 2016

Nutrition and breast cancer; starving triple negative breast cancer cells to death: an interview with Associate Professor Jeff Holst

While there are a range of reports that different foods and food groups can increase or decrease your risk of cancer, these associations are very difficult to scientifically verify.

27 Jan 2016

Study shows rare HER2 missense mutations do not spread breast cancer on their own

Results of a new laboratory study by Johns Hopkins Kimmel Cancer Center researchers suggests that some rare “missense” mutations in the HER2 gene are apparently not — on their own — capable of causing breast cancer growth or spread.

12 Nov 2015

Drugs that target malignant cells increase life expectancy in advanced breast cancer patients

Clinical studies show that new drugs that target malignant cells of HER2-positive breast cancer, such as Pertuzumab and Trastuzumab Emtansine (T-DM1), increase life expectancy in patients with advanced breast cancer.

5 Nov 2015

New campaign raises awareness of City of Hope's life-saving mission and impact

Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.

31 Oct 2015

Breastfeeding associated with lower risk of developing hormone-receptor negative breast cancer

A large international study shows that breastfeeding is associated with a lower risk of developing an aggressive form of breast cancer called hormone-receptor negative. This new combined evidence shows the risk was reduced by up to 20% in women who breastfed.

29 Oct 2015

New drug delivery method could be used to target cancer, tuberculosis

Scientists have designed a novel method for improving the delivery of therapeutic molecules into diseased cells such as those found in cancer and tuberculosis.

23 Oct 2015

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

Disabling a cancer-causing pathway and administering an immune-molecule-based mop-up therapy eradicated a specific type of breast tumor in mice, according to researchers in the Perelman School of Medicine at the University of Pennsylvania.

8 Oct 2015

Scientists trace out intricate molecular pathway that may explain tamoxifen resistance in breast cancer patients

For reasons unknown, many patients with breast cancer treated with the estrogen receptor-blocking drug tamoxifen eventually become resistant to the treatment despite the fact that their cancer cells still have the estrogen receptor proteins that the drug normally targets.

24 Sep 2015

HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

HUYA Bioscience International (HUYA) today announced expanding clinical trials with its lead cancer drug, HBI-8000, starting with a Phase 1 combination trial in support of a breast cancer program to be conducted in the United States.

3 Sep 2015

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

UCLA's Jonsson Comprehensive Cancer Center is ranked among the top 10 cancer centers in the nation, according to a U.S. News & World Report survey of board-certified physicians from across the country. The survey reviewed patient outcomes, the cancer center's reputation among physicians, mortality rates and other care-related factors.

22 Jul 2015

Breast cancer treatment market estimated to increase to over $13.1 billion by 2020

Analysis from business intelligence provider GBI Research - Breast Cancer Therapeutics in Major Developed Markets to 2020 - forecasts the breast cancer treatment market to increase in value from $9.2 billion in 2013 to more than $13.1 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.1%.

24 Jun 2015

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

Stony Brook University has entered into a licensing agreement with a startup company, CadheRx Therapeutics, to develop and market an anti-cancer technology discovered by Sabine Brouxhon, MD, Clinical Associate Professor in the Department of Emergency Medicine at Stony Brook University School of Medicine.

16 Jun 2015

New strategy involving three-pronged approach may keep lung cancer aside

Lung cancer is the leading cause of cancer death worldwide, responsible for some 1.59 million deaths a year. That figure is due, in part, to the fact that lung cancer often returns after what seems at first to be successful treatment. However, the recurring cancer is often resistant to the chemotherapy and other drugs that originally drove it into remission.

4 Jun 2015

Palbociclib drug shows promise in women with HR+ metastatic breast cancer

Despite advances in managing and curing some forms of breast cancer, women whose disease becomes metastatic have fewer effective options. A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer.

30 May 2015

Researchers identify molecular switch for protein that causes HER2-positive breast cancer

Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance.

28 Apr 2015

Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Despite the availability of approximately 25 drugs for the treatment of breast cancer, the unmet need in the global market is vast. To address this drawback, pharmaceutical companies have established a robust pipeline that currently has about 52 drugs in development. While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted drugs is on the rise.

17 Mar 2015

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).

12 Mar 2015